Plasma amyloid β-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease

Archives of Neurology

Volumn 65, Issue 6, 2008, Pages 776-785

  Locascio, Joseph J ^a   Fukumoto, Hiroaki ^a,b   Yap, Liang ^a   Bottiglieri, Teodoro ^c   Growdon, John H ^a   Hyman, Bradley T ^a   Irizarry, Michael C ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Takeda Chemical Company   (Japan)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; C REACTIVE PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ASSESSMENT; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; RATING SCALE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 45149096784     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.6.776     Document Type: Article

References (40)

1. Heyman A, Peterson B, Fillenbaum G, Pieper C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part XIV: demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology. 1996;46(3):656-660.
2. Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc. 1991;39(9):932-941.
3. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part IV: rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43(12):2457-2465.
4. Weintraub S. The record of independent living: an informant-completed measure of activities of daily living and behavior in elderly patients with cognitive impairment. Am J Alzheimer Dis. 1986;1(2):35-39.
5. Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease [published correction appears in Alzheimer Dis Assoc Disord. 2002;16(1):48]. Alzheimer Dis Assoc Disord. 2001;15(4):174-183.
6. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65(12):1888-1893.
7. Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185-1190.
8. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-660.
9. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease [published correction appears in Arch Neurol. 2007;64(9):1246]. Arch Neurol. 2007;64(3):354-362.
10. Sundelöf J, Giedraitis V, Irizarry MC, et al. Plasma beta amyloid and the risk of Alzheimer's disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol. 2008;65(2):256-263.
11. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483.
12. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol. 2004;61(5):668-672.
13. Teunissen CE, van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol. 2003;134(1-2):142-150.
14. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61(1):76-80.
15. Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004;1(2):226-234.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
17. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797-811.
18. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60(7):958-964.
19. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565(1-2):441-446.
20. Gómez-Isla T, Hollister R, West KL, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41(1):17-24.
21. Ingelsson M, Fukumoto H, Newell KL, et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925-931.
22. Locascio JJ, Growdon JH, Corkin S. Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol. 1995;52(11):1087-1099.
23. Assini A, Cammarata S, Vitali A, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63(5):828-831.
24. Kosaka T, Imagawa M, Seki K, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology. 1997;48(3):741-745.
25. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46(3):412-416.
26. Mehta PD, Pirttilaä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57(1):100-105.
27. Pesaresi M, Lovati C, Bertora P, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27(6):904-905.
28. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
29. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996;141(1-2):65-68.
30. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7(4):245-258.
31. Qiu WQ, Sun X, Selkoe DJ, et al. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry. 2006;22(6):536-542.
32. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Aβ levels do not reflect brain Aβ levels. J Neuropathol Exp Neurol. 2007;66(4):264-271.
33. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52(2):168-174.
34. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons Inc; 2004.
35. Suh GH, Ju YS, Yeon BK, Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry. 2004;19(9):817-824.
36. Rasmusson DX, Carson KA, Brookmeyer R, Kawas C, Brandt J. Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cogn. 1996;31(2):133-147.
37. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005;62(3):454-459.
38. Dal Forno G, Rasmusson DX, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol. 1996;53(4):345-350.
39. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996;47(2):444-448.
40. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50(1):3-32.